Analysts Expect INmune Bio, Inc. (NASDAQ:INMB) Will Post Earnings of -$0.68 Per Share

Analysts forecast that INmune Bio, Inc. (NASDAQ:INMBGet Rating) will announce earnings of ($0.68) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for INmune Bio’s earnings. INmune Bio posted earnings of ($0.44) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 54.5%. The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that INmune Bio will report full-year earnings of ($2.27) per share for the current financial year. For the next fiscal year, analysts anticipate that the firm will post earnings of ($3.12) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow INmune Bio.

INmune Bio (NASDAQ:INMBGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. During the same period in the previous year, the business posted ($0.32) earnings per share.

Several brokerages have recently commented on INMB. Zacks Investment Research raised INmune Bio from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 10th. B. Riley cut their price objective on INmune Bio from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, January 24th. Finally, Maxim Group restated a “buy” rating and set a $22.00 price objective on shares of INmune Bio in a research report on Friday, March 4th.

Several hedge funds have recently added to or reduced their stakes in the company. ACT Capital L.L.C. purchased a new stake in INmune Bio during the 3rd quarter worth $5,341,000. BlackRock Inc. boosted its position in INmune Bio by 59.3% during the 4th quarter. BlackRock Inc. now owns 233,265 shares of the company’s stock worth $2,379,000 after purchasing an additional 86,836 shares during the period. Millennium Management LLC boosted its position in INmune Bio by 22.0% during the 4th quarter. Millennium Management LLC now owns 150,680 shares of the company’s stock worth $1,537,000 after purchasing an additional 27,169 shares during the period. Royal Bank of Canada boosted its position in INmune Bio by 90.2% during the 3rd quarter. Royal Bank of Canada now owns 126,411 shares of the company’s stock worth $2,455,000 after purchasing an additional 59,953 shares during the period. Finally, Geode Capital Management LLC boosted its position in INmune Bio by 32.0% during the 4th quarter. Geode Capital Management LLC now owns 118,270 shares of the company’s stock worth $1,206,000 after purchasing an additional 28,663 shares during the period. Institutional investors and hedge funds own 13.91% of the company’s stock.

Shares of NASDAQ:INMB opened at $7.51 on Wednesday. The business’s 50 day simple moving average is $7.82 and its 200-day simple moving average is $10.39. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.95 and a quick ratio of 18.95. INmune Bio has a 12 month low of $6.18 and a 12 month high of $30.37.

About INmune Bio (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Featured Articles

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.